83 FR 23282 - Findings of Research Misconduct
DEPARTMENT OF HEALTH AND HUMAN SERVICES Federal Register Volume 83, Issue 97 (May 18, 2018)
Federal Register Volume 83, Issue 97 (May 18, 2018)
| Page Range | 23282-23282 | |
| FR Document | 2018-10592 |
[Federal Register Volume 83, Number 97 (Friday, May 18, 2018)] [Notices] [Page 23282] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2018-10592] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Findings of Research Misconduct AGENCY: Office of the Secretary, HHS. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: Findings of research misconduct have been made on the part of Maria Cristina Miron Elqutub, Research Interviewer, University of Texas MD Anderson Cancer Center (MDACC). Dr. Elqutub engaged in research misconduct in research supported by National Institute of Dental and Craniofacial Research (NIDCR), National Institutes of Health (NIH), grant U01 DE019765-01. The administrative actions, including three (3) years of supervision, were implemented beginning on April 26, 2018, and are detailed below. FOR FURTHER INFORMATION CONTACT: Wanda K. Jones, Dr.P.H., Interim Director, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453-8200. SUPPLEMENTARY INFORMATION: Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case: Maria Cristina Miron Elqutub, University of Texas MD Anderson Cancer Center: Based on Respondent's admission, the report of an inquiry conducted by MDACC, and analysis conducted by ORI in its oversight review, ORI found that Ms. Maria Cristina Miron Elqutub, Research Interviewer, MDACC, engaged in research misconduct in research supported by NIDCR, NIH, grant U01 DE019765-01. ORI found that Respondent engaged in research misconduct by intentionally and knowingly falsifying and/or fabricating data that were included in the following two (2) published papers and two (2) grant progress reports submitted to NIDCR, NIH:PLoS One 10(6):e0128753, 2015 Jun 2 (hereafter referred to as ``PLoS One 2015''). Cancer 121(14):2367-74, 2015 Jul 15 (hereafter referred to as ``Cancer 2015'') Retracted in: Cancer 124(4):869, 2018 Feb 15. 5 U01 DE019765-04. 5 U01 DE019765-05. Specifically, ORI found that Respondent engaged in research misconduct by recording dates and providing her own blood samples to cause these samples to be falsely labeled as samples from ninety-eight (98) study subjects in a cancer genetics study involving human blood samples. This resulted in the reporting of false data in Tables 1, 2, 3, and 4 in PLoS One 2015, in Figure 1 and Tables 1, 2, 3, and 4 in Cancer 2015, and in the Results sections of Project 2 progress reports for NIDCR, NIH, grants 5 U01 DE019765-04 and 5 U01 DE019765-05. Ms. Elqutub entered into a Voluntary Settlement Agreement and voluntarily agreed, beginning on April 26, 2018: (1) To have her research supervised for a period of three (3) years; Respondent agreed to ensure that prior to the submission of an application for U.S. Public Health Service (PHS) support for a research project on which Respondent's participation is proposed and prior to Respondent's participation in any capacity on PHS-supported research, the institution employing her must submit a plan for supervision of Respondent's duties to ORI for approval; the supervision plan must be designed to ensure the scientific integrity of Respondent's research contribution; Respondent agreed that she will not participate in any PHS-supported research until a supervision plan is submitted to and approved by ORI; Respondent agreed to maintain responsibility for compliance with the agreed upon supervision plan; (2) that for a period of three (3) years, any institution employing her must submit, in conjunction with each application for PHS funds, or report, manuscript, or abstract involving PHS-supported research in which Respondent is involved, a certification to ORI that the data provided by Respondent are based on actual experiments or are otherwise legitimately derived and that the data, procedures, and methodology are accurately reported in the application, report, manuscript, or abstract; (3) if no supervisory plan is provided to ORI, to provide certification to ORI on an annual basis for a period of three (3) years that she has not engaged in, applied for, or had her name included on any application, proposal, or other request for PHS funds without prior notification to ORI; (4) to exclude herself voluntarily from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant for a period of three (3) years; and (5) to the correction or retraction of PLoS One 10(6):e0128753, 2015 Jun 2. Wanda K. Jones, Interim Director, Office of Research Integrity. [FR Doc. 2018-10592 Filed 5-17-18; 8:45 am] BILLING CODE 4150-31-P
![23282 Federal Register / Vol. 83, No. 97 / Friday, May 18, 2018 / Notices
clearance. For U.S. citizens, please • Cancer 121(14):2367–74, 2015 Jul (4) to exclude herself voluntarily from
RSVP no later than Monday, June 25, 15 (hereafter referred to as ‘‘Cancer serving in any advisory capacity to PHS
2018. Written comments are welcome 2015’’) Retracted in: Cancer 124(4):869, including, but not limited to, service on
and encouraged, even if you are 2018 Feb 15. any PHS advisory committee, board,
planning to attend in person. Please • 5 U01 DE019765–04. and/or peer review committee, or as a
send them to the email address: • 5 U01 DE019765–05. consultant for a period of three (3) years;
us.who.irhp@hhs.gov. Specifically, ORI found that and
Dated: May 9, 2018. Respondent engaged in research (5) to the correction or retraction of
misconduct by recording dates and PLoS One 10(6):e0128753, 2015 Jun 2.
G. Garrett Grigsby,
Director for Global Affairs.
providing her own blood samples to Wanda K. Jones,
cause these samples to be falsely labeled Interim Director, Office of Research Integrity.
[FR Doc. 2018–10634 Filed 5–17–18; 8:45 am]
as samples from ninety-eight (98) study
BILLING CODE 4150–38–P [FR Doc. 2018–10592 Filed 5–17–18; 8:45 am]
subjects in a cancer genetics study
BILLING CODE 4150–31–P
involving human blood samples. This
DEPARTMENT OF HEALTH AND resulted in the reporting of false data in
HUMAN SERVICES Tables 1, 2, 3, and 4 in PLoS One 2015, DEPARTMENT OF HEALTH AND
in Figure 1 and Tables 1, 2, 3, and 4 in HUMAN SERVICES
Findings of Research Misconduct Cancer 2015, and in the Results sections
of Project 2 progress reports for NIDCR, National Institutes of Health
AGENCY: Office of the Secretary, HHS. NIH, grants 5 U01 DE019765–04 and 5
ACTION: Notice. U01 DE019765–05. Center for Scientific Review; Notice of
Ms. Elqutub entered into a Voluntary Closed Meetings
SUMMARY: Findings of research Settlement Agreement and voluntarily
misconduct have been made on the part Pursuant to section 10(d) of the
agreed, beginning on April 26, 2018: Federal Advisory Committee Act, as
of Maria Cristina Miron Elqutub, (1) To have her research supervised
Research Interviewer, University of amended, notice is hereby given of the
for a period of three (3) years; following meetings.
Texas MD Anderson Cancer Center Respondent agreed to ensure that prior
(MDACC). Dr. Elqutub engaged in The meetings will be closed to the
to the submission of an application for public in accordance with the
research misconduct in research U.S. Public Health Service (PHS)
supported by National Institute of provisions set forth in sections
support for a research project on which 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
Dental and Craniofacial Research Respondent’s participation is proposed
(NIDCR), National Institutes of Health as amended. The grant applications and
and prior to Respondent’s participation the discussions could disclose
(NIH), grant U01 DE019765–01. The in any capacity on PHS-supported
administrative actions, including three confidential trade secrets or commercial
research, the institution employing her property such as patentable material,
(3) years of supervision, were must submit a plan for supervision of
implemented beginning on April 26, and personal information concerning
Respondent’s duties to ORI for approval; individuals associated with the grant
2018, and are detailed below. the supervision plan must be designed applications, the disclosure of which
FOR FURTHER INFORMATION CONTACT: to ensure the scientific integrity of would constitute a clearly unwarranted
Wanda K. Jones, Dr.P.H., Interim Respondent’s research contribution; invasion of personal privacy.
Director, Office of Research Integrity, Respondent agreed that she will not
1101 Wootton Parkway, Suite 750, Name of Committee: Population Sciences
participate in any PHS-supported
and Epidemiology Integrated Review Group;
Rockville, MD 20852, (240) 453–8200. research until a supervision plan is Social Sciences and Population Studies A
SUPPLEMENTARY INFORMATION: Notice is submitted to and approved by ORI; Study Section.
hereby given that the Office of Research Respondent agreed to maintain Date: June 6, 2018.
Integrity (ORI) has taken final action in responsibility for compliance with the Time: 8:30 a.m. to 6:00 p.m.
the following case: agreed upon supervision plan; Agenda: To review and evaluate grant
Maria Cristina Miron Elqutub, (2) that for a period of three (3) years, applications.
Place: Melrose Hotel, 2430 Pennsylvania
University of Texas MD Anderson any institution employing her must
Ave. NW, Washington, DC 20037.
Cancer Center: Based on Respondent’s submit, in conjunction with each Contact Person: Suzanne Ryan, Ph.D.,
admission, the report of an inquiry application for PHS funds, or report, Scientific Review Officer, Center for
conducted by MDACC, and analysis manuscript, or abstract involving PHS- Scientific Review, National Institutes of
conducted by ORI in its oversight supported research in which Health, 6701 Rockledge Drive, Room 3139,
review, ORI found that Ms. Maria Respondent is involved, a certification MSC 7770, Bethesda, MD 20892, (301) 435–
Cristina Miron Elqutub, Research to ORI that the data provided by 1712, ryansj@csr.nih.gov.
Interviewer, MDACC, engaged in Respondent are based on actual Name of Committee: Cell Biology
research misconduct in research experiments or are otherwise Integrated Review Group; Development—1
Study Section.
supported by NIDCR, NIH, grant U01 legitimately derived and that the data,
Date: June 12, 2018.
DE019765–01. procedures, and methodology are Time: 10:00 a.m. to 6:00 p.m.
ORI found that Respondent engaged accurately reported in the application, Agenda: To review and evaluate grant
in research misconduct by intentionally report, manuscript, or abstract; applications.
and knowingly falsifying and/or (3) if no supervisory plan is provided Place: National Institutes of Health, 6701
daltland on DSKBBV9HB2PROD with NOTICES
fabricating data that were included in to ORI, to provide certification to ORI Rockledge Drive, Bethesda, MD 20892
the following two (2) published papers on an annual basis for a period of three (Virtual Meeting).
and two (2) grant progress reports (3) years that she has not engaged in, Contact Person: Thomas Beres, Ph.D.,
Scientific Review Officer, Center for
submitted to NIDCR, NIH: applied for, or had her name included Scientific Review, National Institutes of
• PLoS One 10(6):e0128753, 2015 Jun on any application, proposal, or other Health, 6701 Rockledge Drive, Room 5148,
2 (hereafter referred to as ‘‘PLoS One request for PHS funds without prior MSC 7840, Bethesda, MD 20892, 301–435–
2015’’). notification to ORI; 1175, berestm@mail.nih.gov.
VerDate Sep<11>2014 16:38 May 17, 2018 Jkt 244001 PO 00000 Frm 00031 Fmt 4703 Sfmt 4703 E:\FR\FM\18MYN1.SGM 18MYN1](https://thefederalregister.org/doc/83_FR_23379/page/1.svg)
Document Created: 2018-05-18 02:16:02
Document Modified: 2018-05-18 02:16:02
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Action | Notice. | |
| Contact | Wanda K. Jones, Dr.P.H., Interim Director, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453-8200. | |
| FR Citation | 83 FR 23282 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR